These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 3876517

  • 1. Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome.
    Tomizawa S, Maruyama K, Nagasawa N, Suzuki S, Kuroume T.
    Nephron; 1985; 41(2):157-60. PubMed ID: 3876517
    [Abstract] [Full Text] [Related]

  • 2. Transforming growth factor-beta1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Nephron; 2001 Feb; 87(2):111-7. PubMed ID: 11244304
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-18 and interleukin-12 synergize to stimulate the production of vascular permeability factor by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Nephron; 2000 Jun; 85(2):127-33. PubMed ID: 10867518
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of vascular permeability factor production by ciclosporin in minimal change nephrotic syndrome.
    Maruyama K, Tomizawa S, Seki Y, Arai H, Kuroume T.
    Nephron; 1992 Jun; 62(1):27-30. PubMed ID: 1436287
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-15 and interleukin-12 have an additive effect on the release of vascular permeability factor by peripheral blood mononuclear cells in normals and in patients with nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Clin Nephrol; 1999 Jul; 52(1):10-8. PubMed ID: 10442490
    [Abstract] [Full Text] [Related]

  • 6. Vascular permeability increasing factor (VPF) in IgA nephropathy.
    Bakker WW, Beukhof JR, van Luijk WH, van der Hem GK.
    Clin Nephrol; 1982 Oct; 18(4):165-7. PubMed ID: 7140031
    [Abstract] [Full Text] [Related]

  • 7. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Nephron; 1999 Oct; 82(1):32-8. PubMed ID: 10224482
    [Abstract] [Full Text] [Related]

  • 8. Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Nephron; 1998 Oct; 78(4):403-9. PubMed ID: 9578066
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Am J Nephrol; 1999 Oct; 19(1):21-7. PubMed ID: 10085445
    [Abstract] [Full Text] [Related]

  • 10. Studies of glomerular permeability factor (GPF) in focal segmental glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF).
    Kondo S, Yoshizawa N, Kusumi Y, Takeuchi A, Torikata C.
    Clin Nephrol; 1999 Nov; 52(5):278-84. PubMed ID: 10584990
    [Abstract] [Full Text] [Related]

  • 11. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome.
    Heslan JM, Branellec AI, Pilatte Y, Lang P, Lagrue G.
    Clin Exp Immunol; 1991 Oct; 86(1):157-62. PubMed ID: 1914229
    [Abstract] [Full Text] [Related]

  • 12. Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Clin Nephrol; 2001 Apr; 55(4):269-74. PubMed ID: 11334311
    [Abstract] [Full Text] [Related]

  • 13. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis.
    Matsumoto K.
    Nephron; 1997 Apr; 75(2):154-9. PubMed ID: 9041534
    [Abstract] [Full Text] [Related]

  • 14. FK 506 for vascular permeability factor production in minimal change nephrotic syndrome.
    Maruyama K, Tomizawa S, Seki Y, Arai H, Ogawa T, Kuroume T.
    Nephron; 1994 Apr; 66(4):486-7. PubMed ID: 7517020
    [No Abstract] [Full Text] [Related]

  • 15. Increased IL-12 release by monocytes in nephrotic patients.
    Matsumoto K, Kanmatsuse K.
    Clin Exp Immunol; 1999 Aug; 117(2):361-7. PubMed ID: 10444271
    [Abstract] [Full Text] [Related]

  • 16. Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome.
    Yoshizawa N, Kusumi Y, Matsumoto K, Oshima S, Takeuchi A, Kawamura O, Kubota T, Kondo S, Niwa H.
    Nephron; 1989 Aug; 51(3):370-6. PubMed ID: 2918948
    [Abstract] [Full Text] [Related]

  • 17. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis.
    Matsumoto K, Ohi H, Kanmatsuse K.
    Nephron; 1997 Aug; 77(2):212-8. PubMed ID: 9346389
    [Abstract] [Full Text] [Related]

  • 18. Augmented interleukin-18 production by peripheral blood monocytes in patients with minimal-change nephrotic syndrome.
    Matsumoto K, Kanmatsuse K.
    Am J Nephrol; 2001 Aug; 21(1):20-7. PubMed ID: 11275628
    [Abstract] [Full Text] [Related]

  • 19. Studies of T lymphocyte function and inhibitory factors in minimal change nephrotic syndrome.
    Tomizawa S, Suzuki S, Oguri M, Kuroume T.
    Nephron; 1979 Aug; 24(4):179-82. PubMed ID: 315034
    [Abstract] [Full Text] [Related]

  • 20. [In vitro production of a human lymphokine by a specific mitogen in primary glomerular nephropathies].
    Laurent J, Heslan JM, Branellec A, Lagrue G.
    Ann Biol Clin (Paris); 1984 Aug; 42(3):207-10. PubMed ID: 6476490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.